LILY34:BVMF
Eli Lilly and Company
250,56 BRL
0,00%
(0,00) 1 D.
11-06, 18:07:00 GMT−3 · BRL
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „LILY34“ įžvalgos...
Atidaryti
250,00 BRL
Aukšta
252,20 BRL
Žema
245,80 BRL
Rinkos kapitalizacija
1,27 trln.
Vid. kiekis
50,56 tūkst.
Apimtis
58,41 tūkst.
52 sav. aukšta
265,00 BRL
52 sav. žema
141,70 BRL
Neapmokėtos akcijos
940,75 mln.
Darbuotojų skaičius
50 tūkst.
Atidaryti
250,00 BRL
Aukšta
252,20 BRL
Žema
245,80 BRL
Rinkos kapitalizacija
1,27 trln.
Vid. kiekis
50,56 tūkst.
Apimtis
58,41 tūkst.
52 sav. aukšta
265,00 BRL
52 sav. žema
141,70 BRL
Neapmokėtos akcijos
940,75 mln.
Darbuotojų skaičius
50 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
Endpoints News
·
prieš 6 valandas
Novo’s race to catch Lilly; Q3 earnings recap; and more
The Motley Fool
·
prieš 17 valandų
Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence
Investor's Business Daily
·
prieš 20 valandų
Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly
Coinbase
·
prieš 1 dieną
About Eli Lilly and Co (Stove Tokenized Stock)
Profilis
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. Its products are marketed in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so.
The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia
Apie „Eli Lilly and Company“
Generalinis direktoriusDavid A. Ricks
Darbuotojai50 tūkst.
Įkurta1876
Pagrindinė būstinėIndianapolis, Indiana, Jungtinės Valstijos
SektoriusHealth Care
Pramonės sritis-
Svetainėlilly.com